Posted by Michael Wonder on 16 Mar 2021
Breast cancer patients can access new interest free payment plan for genomic test that may help them avoid chemotherapy
15 March 2021 - The Oncotype DX Breast Recurrence Score Test now able to be funded via 6 to 24 month interest free payment plans.
Breast cancer patients who wish to have a genomic test that may help them to avoid chemotherapy can now take out interest-free payment plans of up to two years to pay for the test, following an exclusive arrangement between independent pharmaceutical company Specialised Therapeutics Australia and Latitude Finance.
